Want to see DERM full AI Analyst Report?
Journey Medical Corp (DERM) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Minocycline Hydrochloride Capsules | Rosacea | Phase I | Completed | Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks | Oct 24, 2022 | ― |
| Dfd-29 (Minocycline) Fasting, Dfd-29 (Minocycline) Fed, Solodyn (Minocycline) Fasting | Pharmacokinetics | Phase I | Completed | A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects | Jun 19, 2022 | ― |
| Dfd-29, Doxycycline | Papulopustular Rosacea | Phase III | Completed | A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2) | Apr 18, 2022 | ― |
| Dfd-29, Doxycycline | Papulopustular Rosacea | Phase III | Completed | A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea. | Mar 17, 2022 | ― |
| Vehicle, Glycopyrronium Cloth, 2.4% | Palmar Hyperhidrosis | Phase II | Completed | A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis | Mar 15, 2019 | ― |
| Glycopyrronium Topical Wipes | Hyperhidrosis | Phase III | Completed | Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis | Sep 15, 2015 | ― |
| Vehicle, Glycopyrronium Topical Wipes | Hyperhidrosis | Phase III | Completed | Study of Glycopyrronium in Axillary Hyperhydrosis | Aug 19, 2015 | ― |
| Vehicle, Glycopyrronium Topical Wipes | Hyperhidrosis | Phase III | Completed | Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis | Aug 19, 2015 | ― |
| Vehicle, Dose 1 Of Glycopyrrolate, 2.0% Qd, Dose 2 Of Glycopyrrolate, 3.0% Qd, Dose 1 Of Glycopyrronium, 2.5% Qd, Dose 2 Of Glycopyrronium, 3.75% Qd | Hyperhidrosis | Phase II | Completed | Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis | Apr 30, 2014 | ― |
| Vehicle, Glycopyrrolate, 1.0%, Glycopyrrolate, 2.0%, Glycopyrrolate, 3.0%, Glycopyrrolate, 4.0% | Hyperhidrosis | Phase II | Completed | A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis | Dec 16, 2013 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Minocycline Hydrochloride Capsules | Phase I | Rosacea | Completed | Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks | Oct 24, 2022 | ― |
| Dfd-29 (Minocycline) Fasting, Dfd-29 (Minocycline) Fed, Solodyn (Minocycline) Fasting | Phase I | Pharmacokinetics | Completed | A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects | Jun 19, 2022 | ― |
| Dfd-29, Doxycycline | Phase III | Papulopustular Rosacea | Completed | A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2) | Apr 18, 2022 | ― |
| Dfd-29, Doxycycline | Phase III | Papulopustular Rosacea | Completed | A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea. | Mar 17, 2022 | ― |
| Vehicle, Glycopyrronium Cloth, 2.4% | Phase II | Palmar Hyperhidrosis | Completed | A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis | Mar 15, 2019 | ― |
| Glycopyrronium Topical Wipes | Phase III | Hyperhidrosis | Completed | Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis | Sep 15, 2015 | ― |
| Vehicle, Glycopyrronium Topical Wipes | Phase III | Hyperhidrosis | Completed | Study of Glycopyrronium in Axillary Hyperhydrosis | Aug 19, 2015 | ― |
| Vehicle, Glycopyrronium Topical Wipes | Phase III | Hyperhidrosis | Completed | Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis | Aug 19, 2015 | ― |
| Vehicle, Dose 1 Of Glycopyrrolate, 2.0% Qd, Dose 2 Of Glycopyrrolate, 3.0% Qd, Dose 1 Of Glycopyrronium, 2.5% Qd, Dose 2 Of Glycopyrronium, 3.75% Qd | Phase II | Hyperhidrosis | Completed | Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis | Apr 30, 2014 | ― |
| Vehicle, Glycopyrrolate, 1.0%, Glycopyrrolate, 2.0%, Glycopyrrolate, 3.0%, Glycopyrrolate, 4.0% | Phase II | Hyperhidrosis | Completed | A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis | Dec 16, 2013 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Journey Medical Corporation (DERM) have in its pipeline
Journey Medical Corp DERM is currently developing the following drugs: Minocycline Hydrochloride Capsules, Dfd-29 (Minocycline) Fasting, Dfd-29 (Minocycline) Fed, Solodyn (Minocycline) Fasting, Dfd-29, Doxycycline, Vehicle, Glycopyrronium Cloth, 2.4%, Glycopyrronium Topical Wipes, Vehicle, Glycopyrronium Topical Wipes, Vehicle, Dose 1 Of Glycopyrrolate, 2.0% Qd, Dose 2 Of Glycopyrrolate, 3.0% Qd, Dose 1 Of Glycopyrronium, 2.5% Qd, Dose 2 Of Glycopyrronium, 3.75% Qd, Vehicle, Glycopyrrolate, 1.0%, Glycopyrrolate, 2.0%, Glycopyrrolate, 3.0%, Glycopyrrolate, 4.0%. These drug candidates are in various stages of clinical development as the company works toward FDA approval.